3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase NA
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Head & Neck
3
Gastrointestinal
3
NET
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
Conditions
Neuroendocrine Tumors
43
Carcinoma, Neuroendocrine
22
Small Cell Lung Carcinoma
13
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
11
Sarcoma
10
Lung Neoplasms
9
Thyroid Carcinoma, Anaplastic
7
Thyroid Cancer, Papillary
7
Stomach Neoplasms
7
Pheochromocytoma
7
Paraganglioma
7
Head and Neck Neoplasms
7
Gastro-enteropancreatic neuroendocrine tumor
7
Carcinoid Tumor
7
Thyroid Neoplasms
6
Neoplasm Metastasis
6
Colorectal Neoplasms
6
Ovarian Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Thyroid Diseases
4
Thoracic Neoplasms
4
Respiratory Tract Neoplasms
4
Respiratory Tract Diseases
4
Prostatic Neoplasms
4
Neuroblastoma
4
Neoplasms by Site
4
Multiple Endocrine Neoplasia Type 1
4
Lung Diseases
4
Interventions
pralsetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasms, Glandular and Epithelial
×
Endocrine
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA